Apilyte 2.5 Tablet

About Apilyte 2.5 Tablet

Apilyte 2.5 is a tablet from Renata PLC. It contains apixaban 2.5 mg, a medicine that helps prevent dangerous blood clots.

There are 16 brands of Apixaban listed in Bangladesh. The lowest listed price is Antixa 2.5 mg Tablet at ৳ 10.00 per unit.

What is Apilyte 2.5 Tablet?

Apilyte 2.5 is a tablet manufactured by Renata PLC. It contains apixaban 2.5 mg, which belongs to a group of medicines that inhibit factor Xa, a key step in blood clotting. By slowing clot formation, it helps reduce the risk of stroke and systemic embolism in people with nonvalvular atrial fibrillation, and it is used to prevent deep vein thrombosis after hip or knee replacement surgery. It is also used to treat deep vein thrombosis. The dose is decided by the doctor based on individual needs.

Uses of Apilyte 2.5

Apilyte 2.5 is used in adults to reduce the risk of stroke and systemic embolism in people with nonvalvular atrial fibrillation. It is also used to prevent deep vein thrombosis (DVT), which can lead to pulmonary embolism, after hip or knee replacement surgery, and to treat DVT. The doctor decides whether this medicine is suitable and will determine the correct dose and course for each patient.

How to use Apilyte 2.5

Take Apilyte 2.5 exactly as your doctor prescribes. Swallow the tablet with water. Your doctor will decide the dose and how long you need to take it. Do not stop taking this medicine without talking to your doctor first, because stopping suddenly can raise the risk of clots or stroke. If you miss a dose, follow your doctor's or pharmacist's advice on what to do.

Side effects of Apilyte 2.5

Apilyte 2.5 can cause a skin rash or a severe allergic reaction. Because it reduces clotting, it may also increase the risk of bleeding. Tell your doctor or pharmacist if you notice any unusual symptoms or any bleeding that does not stop. Ask your doctor or pharmacist for a full list of possible side effects and how to recognise them.

Safety and precautions

Before taking Apilyte 2.5, tell your doctor if you have active bleeding or have had a severe allergic reaction to apixaban, as the medicine is not suitable in these cases. Do not stop it without medical advice, because stopping can increase the risk of stroke or clots. Tell your doctor about all other medicines you take. In pregnancy and breastfeeding, the doctor will weigh the benefits and risks. Ask your doctor first if you are pregnant, planning pregnancy, or breastfeeding.

Frequently asked questions

How should I store Apilyte 2.5?

Keep Apilyte 2.5 in a dry place, below 30°C. Protect it from light and keep it out of the reach of children. Do not use it after the expiry date shown on the pack.

What is Apilyte 2.5 used for and what kind of medicine is it?

Apilyte 2.5 is a tablet containing apixaban, a factor Xa inhibitor. It is used to reduce the risk of stroke in nonvalvular atrial fibrillation, to prevent deep vein thrombosis after hip or knee replacement surgery, and to treat deep vein thrombosis. The doctor decides if it is right for you.

What does the generic name apixaban mean?

Apixaban is the generic name of the active ingredient in Apilyte 2.5. It refers to a medicine that inhibits factor Xa, a protein involved in blood clotting, and so helps prevent blood clots from forming.

What should I do if I miss a dose of Apilyte 2.5?

If you miss a dose, ask your doctor or pharmacist what to do. Do not take a double dose to make up for a missed one unless your doctor tells you to. Follow the instructions given by your doctor.

Indications

Apixaban is a factor Xa inhibitor indicated:
  • To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
  • For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery
  • ... Read more
Apixaban is a factor Xa inhibitor indicated:
  • To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
  • For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery
  • For the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy

Pharmacology

Apixaban acts by inhibiting coagulation, and thus prevents development of blood clots. As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of apixaban.

Dosage & Administration

Recommended Dose: The recommended dose of Apixaban for most patients is 5 mg taken orally twice daily.

Dosage Adjustments: The recommended dose of Apixaban is 2.5 mg twice daily in patients with any 2 of the following characteristics: age ≥80 years, body weight ≤60 kg, serum creatinine ≥1.5mg/dl.

CYP3A4 and P-gp inhibitors: When Apixaban is coadministered with drugs that are strong dual inhibitors of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) (e.g. ketoconazole, itraconazole, ritonavir, clarithromycin) the recommended dose is 2.5 mg twice daily.

Missed Dose: If a dose of Apixaban is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice-daily administration should be resumed. The dose should not be doubled to make up for a missed dose.

Discontinuation for Surgery and Other Interventions: Apixaban should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. Apixaban should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be non-critical in location and easily controlled.

Switching from or to Apixaban: Switching from warfarin to Apixaban: Warfarin should be discontinued and Apixaban started when the international normalized ratio (INR) is below 2.0.

Switching from Apixaban to warfarin: Apixaban affects INR, so that INR measurements during co-administration with warfarin may not be useful for determining the appropriate dose of warfarin. If continuous anticoagulation is necessary, discontinue Apixaban and begin both a parenteral anticoagulant and warfarin at the time the next dose of Apixaban would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range.

Switching between Apixaban and anticoagulants other than warfarin: Discontinue one being taken and begin the other at the next scheduled dose.

Interaction

Apixaban is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to Apixaban and increase the risk of bleeding. Inducers of CYP3A4 and P-gp decrease exposure to Apixaban and increase the risk of stroke.

Contraindications

Apixaban is contraindicated in patients with the following conditions: Active pathological bleeding. Severe hypersensitivity reaction to Apixaban (i.e. anaphylactic reactions).

Side Effects

Apixaban can cause a skin rash or severe allergic reaction.

Pregnancy & Lactation

Pregnancy: There are no adequate and well-controlled studies of Apixaban in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. Apixaban should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.

Labor and Delivery: Safety and effectiveness of Apixaban during labor and delivery have not been studied in clinical trials. Consider the risks of bleeding and of stroke in using Apixaban in this condition.

Nursing Mothers: It is unknown whether Apixaban or its metabolites are excreted in human milk. Women should be instructed either to discontinue breastfeeding or to discontinue Apixaban therapy, taking into account the importance of the drug to the mother.

Precautions & Warnings

Increased Risk of Stroke with Discontinuation of Apixaban Discontinuing Apixaban in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from Apixaban to warfarin in clinical trials in patients with nonvalvular atrial fibrillation. If Apixaban must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant.

Overdose Effects

There is no antidote to Apixaban. Overdose of Apixaban increases the risk of bleeding. Activated charcoal may be useful in the management of Apixaban overdose.

Storage Conditions

Keep in a dry place and store below 30°C. Protect from light and keep out of the reach of children.

Alternative brands of Apixaban

Other brands with the same generic name, cheapest first.

Antixa Tablet

2.5 mg

Apixaban

General Pharmaceuticals Ltd.

৳ 10.00 per unit

Apiban Tablet

2.5 mg

Apixaban

NIPRO JMI Pharma Ltd.

৳ 15.00 per unit

Apixa Tablet

2.5 mg

Apixaban

Beximco Pharmaceuticals Ltd.

৳ 15.00 per unit

Antixa Tablet

5 mg

Apixaban

General Pharmaceuticals Ltd.

৳ 20.00 per unit

Apiban Tablet

5 mg

Apixaban

NIPRO JMI Pharma Ltd.

৳ 25.00 per unit

Apixa Tablet

5 mg

Apixaban

Beximco Pharmaceuticals Ltd.

৳ 25.00 per unit

See all 16 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.